138 related articles for article (PubMed ID: 6333963)
1. Determination of complement breakdown fragments C3d and its subfragments in health and disease.
Tamotsu M; Arai K; Fujita S; Hosotsubo K; Hayashi C; Miyai K; Miyano A; Kawanaka K; Takenaka M; Shimizu A
Diagn Immunol; 1984; 2(2):116-21. PubMed ID: 6333963
[TBL] [Abstract][Full Text] [Related]
2. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
Perrin LH; Lambert PH; Miescher PA
J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
[TBL] [Abstract][Full Text] [Related]
4. The complement fixing ability of putative circulating immune complexes in rheumatoid arthritis and its relationship to extra-articular disease.
Bourke BE; Moss IK; Mumford P; Horsfall A; Maini RN
Clin Exp Immunol; 1982 Jun; 48(3):726-32. PubMed ID: 6981475
[TBL] [Abstract][Full Text] [Related]
5. Complement C3c and C3d in plasma and synovial fluid in rheumatoid arthritis.
Berkowicz A; Kappelgaard E; Petersen J; Nielsen H; Ingemann-Hansen T; Halkjaer-Kristensen J; Sørensen H
Acta Pathol Microbiol Immunol Scand C; 1983 Dec; 91(6):397-402. PubMed ID: 6608857
[TBL] [Abstract][Full Text] [Related]
6. Detection of a neoantigen on human C3bi and C3d by monoclonal antibody.
Tamerius JD; Pangburn MK; Müller-Eberhard HJ
J Immunol; 1985 Sep; 135(3):2015-9. PubMed ID: 2410510
[TBL] [Abstract][Full Text] [Related]
7. Measurement of the complement C3 breakdown product C3d by rocket immunoelectrophoresis.
Bourke BE; Moss IK; Maini RN
J Immunol Methods; 1982; 48(1):97-108. PubMed ID: 6799579
[TBL] [Abstract][Full Text] [Related]
8. The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis.
Morrow WJ; Williams DJ; Ferec C; Casburn-Budd R; Isenberg DA; Paice E; Snaith ML; Youinou P; Le Goff P
Ann Rheum Dis; 1983 Dec; 42(6):668-71. PubMed ID: 6606402
[TBL] [Abstract][Full Text] [Related]
9. [Functional analysis of immune complex-rich serum fractions in autoimmune diseases by in vitro C3 activation of fresh blood].
Böhm U; Merétey K; Falus A; Bozsóky S
Z Rheumatol; 1981; 40(3):126-30. PubMed ID: 6456623
[TBL] [Abstract][Full Text] [Related]
10. [Rocket immunoelectrophoresis of C3 and C3d: a simple sensitive method for detecting complement activation in plasma].
Hou JC; Lin YL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1986 Feb; 8(1):58-63. PubMed ID: 2943446
[No Abstract] [Full Text] [Related]
11. Plasma C3d/C3 quotient as a parameter for in vivo complement activation.
Nürnberger W; Bhakdi S
J Immunol Methods; 1984 Nov; 74(1):87-91. PubMed ID: 6334115
[TBL] [Abstract][Full Text] [Related]
12. Correlation of C3d fixing circulating immune complexes with disease activity and clinical parameters in patients with systemic lupus erythematosus.
Sekita K; Doi T; Muso E; Yoshida H; Kanatsu K; Hamashima Y
Clin Exp Immunol; 1984 Mar; 55(3):487-94. PubMed ID: 6608422
[TBL] [Abstract][Full Text] [Related]
13. Activation of classical pathway complement in chronic inflammation. Elevated levels of circulating C3d and C4d split products in rheumatoid arthritis and Crohn's disease.
Petersen NE; Elmgreen J; Teisner B; Svehag SE
Acta Med Scand; 1988; 223(6):557-60. PubMed ID: 3389208
[TBL] [Abstract][Full Text] [Related]
14. [Complement fragment C 3d in the plasma of patients with chronic polyarthritis].
Stannat S; Peter HH; Raspe HH; Deicher H
Z Rheumatol; 1986; 45(2):47-51. PubMed ID: 3487899
[TBL] [Abstract][Full Text] [Related]
15. Complement activation in systemic lupus erythematosus: a marker of inflammation.
Kerr LD; Adelsberg BR; Spiera H
J Rheumatol; 1986 Apr; 13(2):313-9. PubMed ID: 3487647
[TBL] [Abstract][Full Text] [Related]
16. Partial characterization of physiologically generated C3 components expressing C3d but not C3c epitopes.
Siersted HC; Jensenius JC; Svehag SE; Brandslund I
J Clin Lab Immunol; 1983 Dec; 12(4):201-8. PubMed ID: 6198522
[TBL] [Abstract][Full Text] [Related]
17. Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity.
Mallya RK; Vergani D; Tee DE; Bevis L; de Beer FC; Berry H; Hamilton ED; Mace BE; Pepys MB
Clin Exp Immunol; 1982 Jun; 48(3):747-53. PubMed ID: 6981476
[TBL] [Abstract][Full Text] [Related]
18. Quantification by ELISA of erythrocyte-bound C3 fragments expressing C3d and/or C3c epitopes in patients with factor I deficiency and with autoimmune diseases.
Møller Rasmussen J; Jepsen HH; Teisner B; Holmskov-Nielsen U; Rasmussen GG; Svehag SE
Vox Sang; 1989; 56(4):262-9. PubMed ID: 2474900
[TBL] [Abstract][Full Text] [Related]
19. Quantification of the C3 breakdown product C3d by rocket immunoelectrophoresis.
Ramentol-Massana M; Grau G; Beaumariage ML; Salmon J
Int Arch Allergy Appl Immunol; 1982; 68(3):219-21. PubMed ID: 7085116
[TBL] [Abstract][Full Text] [Related]
20. Patients with systemic lupus erythematosus are deficient in complement-dependent prevention of immune precipitation.
Arason GJ; Steinsson K; Kolka R; Víkingsdóttir T; D'Ambrogio MS; Valdimarsson H
Rheumatology (Oxford); 2004 Jun; 43(6):783-9. PubMed ID: 15054157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
